ACE: Acarbose Cardiovascular Evaluation trial
| Dates: | 2008 - 2022 |
|---|---|
| Funding: | Bayer Schering Pharma |
| Collaborators: | Diabetes Trial Unit (DTU), University of Oxford; University of Beijing |
| Information: | Alastair Gray |
The ACE trial is being conducted in Hong Kong and China, and is investigating the effects of an oral anti-diabetes drug containing acarbose on preventing recurrent cardiovascular disease (CVD) and type 2 diabetes in individuals with CVD and pre-diabetes. The trial is recruiting approximately 7,500 individuals with CVD, who also have pre-diabetes. Trial results are expected in 2013.
HERC is conducting the economic analysis alongside the trial.
Our team
In this section